Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Buy
68
NBIX Quote, Financials, Valuation and Earnings
Last price:
$148.69
Seasonality move
:
9.22%
Day range:
$151.12 - $155.55
52-week range:
$84.23 - $160.18
Dividend yield:
0%
P/E ratio:
36.79x
P/S ratio:
5.87x
P/B ratio:
5.11x
Volume:
768.2K
Avg. volume:
1M
1-year change:
21.59%
Market cap:
$15.4B
Revenue:
$2.4B
EPS (TTM):
$4.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
$747.2M | $2.07 | 28.53% | 140.63% | $177.92 |
|
AGEN
Agenus, Inc.
|
$80.4M | $2.20 | 144.6% | -70.59% | $12.33 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$1.4M | -$0.42 | 19.84% | -177.23% | $9.00 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -2.03% | 728.47% | $28.87 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
$154.06 | $177.92 | $15.4B | 36.79x | $0.00 | 0% | 5.87x |
|
AGEN
Agenus, Inc.
|
$3.71 | $12.33 | $126.2M | -- | $0.00 | 0% | 0.94x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$6.16 | $9.00 | $223.8M | -- | $0.00 | 0% | 51.10x |
|
PFE
Pfizer Inc.
|
$26.43 | $28.87 | $150.3B | 15.41x | $0.43 | 6.51% | 2.40x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.74 | $11.00 | $139.9M | 25.04x | $0.00 | 0% | 2.21x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
13.77% | 1.498 | 3.43% | 2.89x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.383 | 285.06% | 0.03x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
216.44% | 3.715 | 164.57% | 0.11x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences, Inc.
|
$780.9M | $239.3M | 13.56% | 15.8% | 30.1% | $214.3M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$789K | -$7.8M | -57.86% | -- | -670.92% | -$4.5M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Neurocrine Biosciences, Inc. vs. Competitors
-
Which has Higher Returns NBIX or AGEN?
Agenus, Inc. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of -116.82%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About NBIX or AGEN?
Neurocrine Biosciences, Inc. has a consensus price target of $177.92, signalling upside risk potential of 15.49%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 232.44%. Given that Agenus, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Agenus, Inc. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 AGENAgenus, Inc.2 1 0 -
Is NBIX or AGEN More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.
-
Which is a Better Dividend Stock NBIX or AGEN?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or AGEN?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Agenus, Inc. quarterly revenues of $30.2M. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Agenus, Inc.'s net income of $63.9M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 36.79x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.87x versus 0.94x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.87x 36.79x $794.9M $209.5M AGENAgenus, Inc.0.94x -- $30.2M $63.9M
-
Which has Higher Returns NBIX or AIM?
AIM ImmunoTech has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of -10571.43%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About NBIX or AIM?
Neurocrine Biosciences, Inc. has a consensus price target of $177.92, signalling upside risk potential of 15.49%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Neurocrine Biosciences, Inc., analysts believe AIM ImmunoTech is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 AIMAIM ImmunoTech1 0 0 -
Is NBIX or AIM More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock NBIX or AIM?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or AIM?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 36.79x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.87x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.87x 36.79x $794.9M $209.5M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns NBIX or ARMP?
Armata Pharmaceuticals, Inc. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of -2301.55%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Armata Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M -
What do Analysts Say About NBIX or ARMP?
Neurocrine Biosciences, Inc. has a consensus price target of $177.92, signalling upside risk potential of 15.49%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 46.1%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 ARMPArmata Pharmaceuticals, Inc.1 0 0 -
Is NBIX or ARMP More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.
-
Which is a Better Dividend Stock NBIX or ARMP?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or ARMP?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 36.79x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.87x versus 51.10x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.87x 36.79x $794.9M $209.5M ARMPArmata Pharmaceuticals, Inc.51.10x -- $1.2M -$26.7M
-
Which has Higher Returns NBIX or PFE?
Pfizer Inc. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of 21.32%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About NBIX or PFE?
Neurocrine Biosciences, Inc. has a consensus price target of $177.92, signalling upside risk potential of 15.49%. On the other hand Pfizer Inc. has an analysts' consensus of $28.87 which suggests that it could grow by 9.24%. Given that Neurocrine Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe Neurocrine Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 PFEPfizer Inc.7 15 1 -
Is NBIX or PFE More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock NBIX or PFE?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.51% to investors and pays a quarterly dividend of $0.43 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or PFE?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Neurocrine Biosciences, Inc.'s net income of $209.5M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 36.79x while Pfizer Inc.'s PE ratio is 15.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.87x versus 2.40x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.87x 36.79x $794.9M $209.5M PFEPfizer Inc.2.40x 15.41x $16.7B $3.6B
-
Which has Higher Returns NBIX or PLX?
Protalix Biotherapeutics, Inc. has a net margin of 26.36% compared to Neurocrine Biosciences, Inc.'s net margin of 13.19%. Neurocrine Biosciences, Inc.'s return on equity of 15.8% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital NBIXNeurocrine Biosciences, Inc.98.24% $2.04 $3.5B PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About NBIX or PLX?
Neurocrine Biosciences, Inc. has a consensus price target of $177.92, signalling upside risk potential of 15.49%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 532.18%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Neurocrine Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NBIXNeurocrine Biosciences, Inc.19 3 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is NBIX or PLX More Risky?
Neurocrine Biosciences, Inc. has a beta of 0.273, which suggesting that the stock is 72.654% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock NBIX or PLX?
Neurocrine Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NBIX or PLX?
Neurocrine Biosciences, Inc. quarterly revenues are $794.9M, which are larger than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Neurocrine Biosciences, Inc.'s net income of $209.5M is higher than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Neurocrine Biosciences, Inc.'s price-to-earnings ratio is 36.79x while Protalix Biotherapeutics, Inc.'s PE ratio is 25.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences, Inc. is 5.87x versus 2.21x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NBIXNeurocrine Biosciences, Inc.5.87x 36.79x $794.9M $209.5M PLXProtalix Biotherapeutics, Inc.2.21x 25.04x $17.9M $2.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 18.2% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 13.35% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is up 3.92% over the past day.
